Search results for "hypercholesterolemia"

showing 10 items of 245 documents

Factor VII Activity Is an Independent Predictor of Cardiovascular Mortality in Elderly Women of a Sicilian Population: Results of an 11-year Follow-up

2002

SummaryThe aim of the Epidemiological project “Ventimiglia di Sicilia” is to identify the cardiovascular risk factors in a Sicilian population with a low risk profile and healthy nutritional habits. The risk of cardiovascular mortality in older subjects (over 60 years of age) is presented for an 11 year follow-up. Females showed higher prevalence of diabetes mellitus, hypertension, obesity and higher levels of total, LDL and HDL cholesterol, factor VII activity and fibrinogen compared to males. Cardiovascular mortality was related to hypertension and obesity in males, to high factor VII activity, obesity and diabetes mellitus in females. In a Logistic Regression model the same variables wer…

MaleSettore MED/09 - Medicina InternaEpidemiologyComorbidityLogistic regressionFibrinogenCohort Studieschemistry.chemical_compoundRisk FactorsEpidemiologyPrevalenceFactor VII activityLipoproteinSicilyeducation.field_of_studyFactor VIISmokingAge FactorsHematologyFactor VIIMiddle AgedCardiovascular diseaseCardiovascular DiseasesHypertensionFemalemedicine.drugAdultRiskmedicine.medical_specialtyHypercholesterolemiaPopulationHyperlipoproteinemia Type IISex FactorsDiabetes mellitusDiabetes MellitusmedicineHumansObesityeducationAgedCoagulationbusiness.industryCholesterolmedicine.diseaseObesitySurgerychemistrybusinessFollow-Up StudiesDemographyThrombosis and Haemostasis
researchProduct

Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study

2018

Abstract Background and aims Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of blood cholesterol from birth and premature coronary heart disease. Thus, the identification of FH patients is crucial to prevent or delay the onset of cardiovascular events, and the availability of a tool helping with the diagnosis in the setting of general medicine is essential to improve FH patient identification. Methods This study evaluated the performance of the Dutch Lipid Clinic Network (DLCN) score in FH patients enrolled in the LIPIGEN study, an Italian integrated network aimed at improving the identification of patients with genetic dyslipidaemias, including FH.…

MaleSettore MED/09 - Medicina InternaGenetic testingPredictive Value of TestFamilial hypercholesterolemia030204 cardiovascular system & hematologyDecision Support Technique0302 clinical medicineRetrospective StudieRisk FactorsCardiovascular DiseaseGenetic MarkerProspective Studies030212 general & internal medicineAge of OnsetProspective cohort studyeducation.field_of_studymedicine.diagnostic_testMiddle AgedDutch Lipid Clinic Network score; Familial hypercholesterolemia; Genetic testing; Adult; Age of Onset; Biomarkers; Cardiovascular Diseases; Cholesterol LDL; Female; Genetic Markers; Genetic Predisposition to Disease; Genetic Testing; Humans; Hyperlipoproteinemia Type II; Italy; Male; Middle Aged; Phenotype; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Decision Support Techniques; Mutation3. Good healthCholesterolPhenotypeItalyCardiovascular DiseasesFemaleCardiology and Cardiovascular MedicineHumanAdultGenetic Markersmedicine.medical_specialtyDutch Lipid Clinic Network scorePopulationFamilial hypercholesterolemiaReproducibility of ResultPhysical examinationDutch Lipid Clinic Network score; Familial hypercholesterolemia; Genetic testing; Cardiology and Cardiovascular MedicineRisk AssessmentLDLDecision Support TechniquesHyperlipoproteinemia Type II03 medical and health sciencesPredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseFirst-degree relativeseducationRetrospective StudiesGenetic testingDutch Lipid Clinic Network score; Familial hypercholesterolemia; Genetic testingbusiness.industryRisk FactorReproducibility of ResultsSettore MED/13 - ENDOCRINOLOGIABiomarkerCholesterol LDLmedicine.diseaseMissing dataDutch Lipid Clinic Network score Familial hypercholesterolemia Genetic testingProspective StudieMutationAge of onsetbusinessBiomarkers
researchProduct

Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy

2017

Homozygous familial hypercholesterolaemia (HoFH) is a rare form of inherited dyslipidemia resistant to conventional cholesterol-lowering medications so that lipoprotein apheresis (LA) is usually required. Lomitapide has been approved for the treatment of HoFH. The aim of this study was to evaluate the benefits of lomitapide in HoFH patients followed with the usual clinical care. Homozygous familial hypercholesterolaemia (HoFH) is a rare form of inherited dyslipidemia resistant to conventional cholesterol-lowering medications so that lipoprotein apheresis (LA) is usually required. Lomitapide has been approved for the treatment of HoFH. The aim of this study was to evaluate the benefits of lo…

MaleSettore MED/09 - Medicina InternaHyperlipidemia Familial Combined030204 cardiovascular system & hematologyPharmacologyBenzimidazolecholesterol-lowering effect; clinical practice; genetics; lomitapide; severe hypercholesterolemia; medicine (all); pharmacology (medical)cholesterol-lowering effectchemistry.chemical_compound0302 clinical medicineRetrospective StudieAnticholesteremic Agentgenetics030212 general & internal medicineAged 80 and overAnticholesteremic AgentsHomozygoteGeneral MedicineMiddle Agedclinical practiceSafety profileItalylipids (amino acids peptides and proteins)FemaleHumanAdultmedicine.medical_specialtySocio-culturaleLiver ultrasoundLDLRAP1 geneHyperlipoproteinemia Type II03 medical and health sciencesGeneticInternal medicinemedicineHumansLiver damagemedicine (all)Familial homozygous hypercholesterolemiaAgedRetrospective Studieslomitapidebusiness.industrysevere hypercholesterolemiamedicine.diseaseRheumatologyLomitapidepharmacology (medical)chemistryBenzimidazolesbusinessDyslipidemia
researchProduct

Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study

2015

Abstract The main guidelines for cardiovascular disease prevention suggest that nutraceuticals could be an efficacious tool to improve lipid pattern. Our aim was to carry out a clinical trial comparing the metabolic effects of a combined nutraceutical containing both red yeast rice and polyunsaturated fatty acids (PUFAs) and a phytosterol-based approach in a setting of clinical practice. This was a multicenter open study with parallel control. We consecutively enrolled 107 pharmacologically untreated subjects affected by primary polygenic hypercholesterolemia and metabolic syndrome, assigned to 8-week treatment with a combined treatment with red yeast rice (Dif1Stat®, including 5 mg monacol…

MaleSettore MED/09 - Medicina InternaMedicine (miscellaneous)PharmacologyTriglycerideDietary supplements; Hypercholesterolemia; Monacolins; Nutraceuticals; Phytosterols; PUFA; Red yeast rice; Medicine (miscellaneous); Nutrition and DieteticsDietary supplementchemistry.chemical_compoundPhytosterolAnticholesteremic AgentMetabolic Syndromechemistry.chemical_classificationMonacolinNutrition and DieteticsAnticholesteremic AgentsPhytosterolPhytosterolsDietary supplements; Hypercholesterolemia; Monacolins; Nutraceuticals; Phytosterols; PUFA; Red yeast rice; Adult; Anticholesteremic Agents; Biological Products; Cholesterol; Cholesterol LDL; Fatty Acids Unsaturated; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Metabolic Syndrome; Middle Aged; Phytosterols; Treatment Outcome; Triglycerides; Dietary Supplements; Medicine (miscellaneous); Nutrition and DieteticsLipidMiddle AgedDietary supplementsLipidsCholesterolTreatment OutcomeBiochemistryFatty Acids UnsaturatedBiological ProductFemalelipids (amino acids peptides and proteins)NutraceuticalNutraceuticalsLovastatinFull CommunicationsHumanmedicine.drugPolyunsaturated fatty acidAdultHypercholesterolemiaBiologyNutraceuticalMonacolinsmedicineRed yeast riceHumansLovastatinTriglyceridesBiological ProductsCholesterolCholesterol LDLmedicine.diseaseClinical trialRed yeast ricechemistryMetabolic syndromePUFAJournal of Medicinal Food
researchProduct

A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in di…

2013

The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to ezetimibe/simvastatin (EZ/S) 10/20 mg versus doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in subjects with cardiovascular disease (CVD) and diabetes was assessed. Endpoints included percentage change in LDL-C and percentage of patients achieving LDL-C <70 mg/dL. Significantly greater reductions in LDL-C occurred when switching to EZ/S versus statin doubling in the overall population and in subjects treated with simvastatin 20 mg or atorvastatin 10 mg (all p < 0.001). The LDL-C reduction was numerically greater when switching to EZ/S vers…

MaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologySeverity of Illness IndexAtorvastatinLongitudinal StudiesRosuvastatin CalciumAged 80 and overeducation.field_of_studySulfonamidesAnticholesteremic AgentsMiddle AgedRosuvastatin CalciumDrug CombinationsCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleDrug MonitoringCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyStatinmedicine.drug_classPopulationHypercholesterolemiaUrologyDiabetes ComplicationsEzetimibeDouble-Blind MethodInternal MedicinemedicineHumansRosuvastatinPyrrolescardiovascular diseaseseducationAgedbusiness.industrynutritional and metabolic diseasesCholesterol LDLFluorobenzenesPyrimidinesSimvastatinHeptanoic AcidsAzetidinesEzetimibe/simvastatinbusinessDiabetic AngiopathiesDiabetesvascular disease research
researchProduct

Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients

2010

BACKGROUND: Reducing low-density lipoprotein cholesterol (LDL-C) is the primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD). METHODS: This double blind placebo-controlled study enrolled patients 18 to 75 years of age with primary hypercholesterolemia and establishedCHDwhowere taking a stable daily dose of simvastatin 20 mg. Patients were randomized to ezetimibe/simvastatin 10/20 mg (eze/simva; n 5 56) or simvastatin 40 mg (simva; n 5 56) for 6 weeks. Percent change from baseline in LDL-C, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were assessed by use of the Student t test. The percent of patients achieving L…

MaleSimvastatinSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismCoronary DiseasePharmacologyGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawCholesterol absorption inhibitorEzetimibe; simvastatin; coronary heart diseaseNutrition and DieteticsAnticholesteremic AgentsMiddle AgedLipidCoronary heart diseaseCholesterolDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmedicine.drug_classHypercholesterolemiaPharmacotherapyDouble-Blind MethodEzetimibeInternal medicineInternal MedicinemedicineHumansTriglyceridesCholesterol absorption inhibitorAgedCholesterolbusiness.industryCholesterol HDLCholesterol absorption inhibitor; Coronary heart disease; Ezetimibe; Lipids; SimvastatinCholesterol LDLEzetimibeClinical trialchemistrySimvastatinAzetidinesEzetimibe/simvastatinbusinessJournal of Clinical Lipidology
researchProduct

Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syn…

2011

Metabolic syndrome (MetS) is a clustering of atherosclerotic coronary heart disease risk factors. This post-hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg in a cohort of 618 high-risk hypercholesterolaemic patients with ( n=368) and without ( n=217) MetS who had previously been on statin monotherapy. Patients were randomised 1:1 to double-blind ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg for 6 weeks. Least squares mean percent change from baseline and 95% confidence intervals in lipid efficacy parameters were calculated for the population and within subgroups. Treatment with ezetimibe/simvastatin was significantly more effect…

MaleSimvastatinSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismEzetimibe Simvastatin Drug CombinationCoronary DiseaseGastroenterologychemistry.chemical_compoundRisk FactorsDrug CombinationAzetidineAnticholesteremic AgentOdds RatioRosuvastatin CalciumMetabolic Syndromeeducation.field_of_studySulfonamidesDrug SubstitutionMetabolic Syndrome XAnticholesteremic AgentsLipidMiddle AgedLipidsEuropeRosuvastatin CalciumDrug CombinationsCholesterolTreatment Outcomelipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular Medicinemedicine.drugHumanmedicine.medical_specialtyStatinLogistic Modelmedicine.drug_classPopulationHypercholesterolemiaSulfonamideRisk AssessmentEzetimibeDouble-Blind MethodInternal medicineInternal MedicinemedicineHumansRosuvastatinLeast-Squares AnalysiseducationAgedApolipoproteins BLeast-Squares AnalysiAnalysis of VarianceCholesterolbusiness.industryRisk FactorFluorobenzenenutritional and metabolic diseasesCholesterol LDLFluorobenzenesEndocrinologyLogistic ModelsPyrimidineschemistryPyrimidineSimvastatinBiological MarkerAzetidinesEzetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkersDiabetesvascular disease research
researchProduct

Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.

2013

Context and Objective Investigating the effects of lipid-lowering drugs on HDL subclasses has shown ambiguous results. This study assessed the effects of ezetimibe, simvastatin, and their combination on HDL subclass distribution. Design and Participants A single-center randomized parallel 3-group open-label study was performed in 72 healthy men free of cardiovascular disease with a baseline LDL-cholesterol of 111±30 mg/dl (2.9±0.8 mmol/l) and a baseline HDL-cholesterol of 64±15 mg/dl (1.7±0.4 mmol/l). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24) or their combination (n = 24) for 14 days. Blood was drawn before and after the treatment period. HDL subc…

MaleSimvastatinlcsh:MedicinePharmacologyBiochemistryLipoprotein MetabolismVascular MedicineSubclasslaw.inventionchemistry.chemical_compoundHigh-density lipoproteinRandomized controlled triallawMedicine and Health SciencesMedicinelcsh:ScienceHypolipidemic AgentsMultidisciplinaryHealthy VolunteersResearch DesignDrug Therapy Combinationlipids (amino acids peptides and proteins)Lipoproteins HDLResearch Articlemedicine.drugAdultmedicine.medical_specialtylipid-lowering drugs high-density lipoprotein healthy menDrug Research and DevelopmentClinical Research DesignLipoproteinsHypercholesterolemiaCardiologyAdipokineContext (language use)Research and Analysis MethodsCardiovascular PharmacologyAdipokinesEzetimibeInternal medicineHumansClinical TrialsPharmacologybusiness.industryCholesterollcsh:RBiology and Life SciencesProteinsnutritional and metabolic diseasesEzetimibeAtherosclerosisGlucoseEndocrinologychemistrySimvastatinAzetidineslcsh:QClinical MedicinebusinessBiomarkersPLoS ONE
researchProduct

Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and …

2011

OBJECTIVE: To evaluate relationships between apolipoprotein B (Apo B), LDL cholesterol (LDL-C), and non-HDL-C in high-risk patients treated with lipid-lowering therapy. DESIGN AND METHODS: This post-hoc analysis calculated LDL-C and non-HDL-C levels corresponding to an Apo B of 0.9 g/L following treatment with 1) statin monotherapy (baseline) and 2) ezetimibe/simvastatin 10/20mg or rosuvastatin 10mg (study end). The percentages of patients reaching LDL-C, non-HDL-C, and Apo B targets were calculated at study end. RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goa…

MaleSimvastatinmedicine.medical_specialtySettore MED/09 - Medicina InternaStatinApolipoprotein Bmedicine.drug_classHypercholesterolemiaClinical BiochemistryCoronary DiseaseGastroenterologyRosuvastatinEzetimibeEzetimibe/simvastatin; Rosuvastatin; Correlation; Apolipoprotein B; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterolInternal medicinemedicineHumansLow-density lipoprotein cholesterolRosuvastatinRosuvastatin CalciumAgedApolipoproteins BLdl cholesterolSulfonamidesbiologyEzetimibe/simvastatinbusiness.industrynutritional and metabolic diseasesGeneral MedicineMiddle AgedEzetimibeCorrelationFluorobenzenesNon-high-density lipoprotein cholesterolCholesterolPyrimidinesSimvastatinNon hdl cholesterolbiology.proteinAzetidinesFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessApolipoprotein Bmedicine.drugClinical Biochemistry
researchProduct

Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: insights from Italian general practice

2018

Background and aims: Statin utilization and lipid goal achievement were estimated in a large sample of Italian patients at high/very-high cardiovascular (CV) risk. Methods: Patients aged ≥18 years with a valid low-density lipoprotein cholesterol (LDL-C) measurement in 2015 were selected from the IMS Health Real World Data database; non-high-density lipoprotein cholesterol (non-HDL-C) was assessed in those with available total cholesterol measurements. Index dates were defined as the last valid lipid measurement in 2015. Patients were hierarchically classified into mutually exclusive risk categories: heterozygous familial hypercholesterolemia (primary and secondary prevention), atheroscler…

MaleTime FactorsSettore MED/09 - Medicina InternaDatabases FactualGeneral PracticeFamilial hypercholesterolemiaDisease030204 cardiovascular system & hematology0302 clinical medicineRisk FactorsCardiovascular disease; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterol; Prevention; StatinMedicine030212 general & internal medicinePractice Patterns Physicians'StrokeAged 80 and overLipid MeasurementMiddle AgedCardiovascular diseaseNon-high-density lipoprotein cholesterolCholesterolTreatment OutcomeItalyCardiovascular DiseasesCohortPractice Guidelines as Topiclipids (amino acids peptides and proteins)FemaleGuideline AdherenceCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute coronary syndromeStatinCardiovascular disease; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterol; Prevention; Statin; Cardiology and Cardiovascular Medicinemedicine.drug_classRisk Assessment03 medical and health sciencesDiabetes mellitusInternal medicineHumansLow-density lipoprotein cholesterolAgedDyslipidemiasRetrospective Studiesbusiness.industryPreventionStatinCholesterol LDLmedicine.diseaseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkers
researchProduct